Leerink Partnrs Has Bullish Estimate for PTCT Q1 Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Investment analysts at Leerink Partnrs increased their Q1 2025 earnings per share (EPS) estimates for shares of PTC Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. Leerink Partnrs analyst J. Schwartz now expects that the biopharmaceutical company will earn $10.04 per share for the quarter, up from their prior estimate of ($1.47). The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share. Leerink Partnrs also issued estimates for PTC Therapeutics' Q2 2025 earnings at ($0.96) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.04) EPS, FY2025 earnings at $8.89 EPS and FY2026 earnings at ($2.99) EPS.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.85 by $9.19. The firm had revenue of $1.18 billion for the quarter, compared to analysts' expectations of $437.16 million. During the same quarter last year, the company posted ($1.20) EPS. The firm's revenue was down 9.6% on a year-over-year basis.

A number of other research analysts also recently weighed in on PTCT. Citigroup upgraded PTC Therapeutics from a "sell" rating to a "neutral" rating and reduced their target price for the stock from $50.00 to $40.00 in a report on Wednesday, May 7th. Scotiabank began coverage on PTC Therapeutics in a research report on Friday, March 7th. They issued a "sector perform" rating and a $55.00 price target on the stock. Robert W. Baird dropped their price target on PTC Therapeutics from $70.00 to $66.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. StockNews.com raised PTC Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Thursday, May 8th. Finally, Barclays dropped their price target on PTC Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, PTC Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $61.92.

PTC Therapeutics Trading Up 0.9%

Shares of PTCT stock traded up $0.42 during midday trading on Friday, reaching $46.81. 607,326 shares of the stock were exchanged, compared to its average volume of 855,552. PTC Therapeutics has a 1 year low of $28.72 and a 1 year high of $58.38. The company's 50 day moving average is $48.62 and its two-hundred day moving average is $47.09. The firm has a market cap of $3.71 billion, a PE ratio of -7.88 and a beta of 0.52.

Institutional Investors Weigh In On PTC Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Smartleaf Asset Management LLC increased its stake in PTC Therapeutics by 78.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 613 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 270 shares in the last quarter. Sterling Capital Management LLC boosted its holdings in shares of PTC Therapeutics by 424.4% during the 4th quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 522 shares during the last quarter. Quantbot Technologies LP boosted its holdings in shares of PTC Therapeutics by 545.5% during the 1st quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 551 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of PTC Therapeutics by 84.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 320 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of PTC Therapeutics by 86.3% during the 1st quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 441 shares during the last quarter.

Insider Activity at PTC Therapeutics

In other news, CFO Pierre Gravier sold 1,168 shares of the company's stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total value of $58,516.80. Following the completion of the sale, the chief financial officer now directly owns 75,603 shares in the company, valued at $3,787,710.30. This represents a 1.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Mark Elliott Boulding sold 1,333 shares of the company's stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total value of $66,783.30. Following the completion of the sale, the vice president now owns 105,515 shares of the company's stock, valued at $5,286,301.50. This trade represents a 1.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,305 shares of company stock valued at $1,682,755. 5.50% of the stock is owned by corporate insiders.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.